Locally Advanced Breast Cancer (LABC)

Also known as: Locally Advanced Breast Cancer / Locally Advance Breast Cancer (LABC) / Malignant neoplasm of breast / Malignant breast neoplasm / Breast cancer / Breast tumor malignant / Breast tumour malignant / Breast cancer NOS / Breast cancer stage unspecified / Ca breast

DrugDrug NameDrug Description
DB01217AnastrozoleAnastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.
DB01248DocetaxelDocetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.
DB04845IxabepiloneIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
DB06366PertuzumabPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
DrugDrug NamePhaseStatusCount
DB09274Artesunate1Completed1
DB01101Capecitabine1Completed1
DB11651Dactolisib1Completed1
DB01259Lapatinib1Completed1
DB00072Trastuzumab1Completed1
DB00112Bevacizumab2Completed1
DB00958Carboplatin2Completed1
DB00958Carboplatin2Not Yet Recruiting1
DB00958Carboplatin2Recruiting1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting2
DB01262Decitabine2Recruiting1
DB01248Docetaxel2Not Yet Recruiting1
DB00997Doxorubicin2Completed1
DB00997Doxorubicin2Not Yet Recruiting1
DB00997Doxorubicin2Recruiting1
DB00441Gemcitabine2Completed1
DB01275Hydralazine2Terminated1
DB12437Irosustat2Completed1
DB01229Paclitaxel2Completed1
DB01229Paclitaxel2Not Yet Recruiting1
DB01229Paclitaxel2Recruiting1
DB00019Pegfilgrastim2Not Yet Recruiting1
DB09037Pembrolizumab2Recruiting1
DB06366Pertuzumab2Not Yet Recruiting1
DB00020Sargramostim2Completed1
DB00072Trastuzumab2Completed1
DB00072Trastuzumab2Not Yet Recruiting1
DB00399Zoledronic acid2Completed1
DB00990Exemestane3Completed1
DB00947Fulvestrant3Completed1
DB00531Cyclophosphamide4Completed1
DB00997Doxorubicin4Completed1
DB01006Letrozole4Completed1